UBS raises Blueprint Medicines' PT on Sanofi's up to $9.5 billion takeover deal

Blueprint Medicines

05/06/2025 17:04

** Brokerage UBS raises PT on biotech firm Blueprint Medicines Corp BPMC.O to $129 from $88; setting it in line with Sanofi's buyout price for the co

** Maintains "neutral" rating

** French drugmaker Sanofi SASY.PA said on Monday it has agreed to buy BPMC for up to $9.5 billion to boost its position in rare immunology diseases

** UBS sees limited or no overlap in both companies' portfolios

** Sanofi gains Ayvakit to treat a type of rare immunology disease called advanced and indolent systemic mastocytosis with $478.9 million revenue in 2024 - UBS

** Including session's moves, stock up 46.9% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))